CRISPR Therapeutics(CRSP) - 2024 Q1 - Quarterly Results

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results —Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications — —Clinical trial ongoing for CTX211™, an allogeneic, hypoimmune, gene-edited, stem cell derived product candidate for the treatment of Type 1 Diabetes (T1D) — ZUG, Switzerland and BOSTON, Mass., May 8, 2024 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceut ...